Order Lifepharm Global Products

Conflict of interest/funding disclosure missing from half of news releases we’ve reviewed — a case study on why that’s important

Conflict of interest/funding disclosure missing from half of news releases we’ve reviewed — a case study on why that’s important

The Effects of Stress on Your Body and Mind Are Staggering! Watch The Video Below To See What You Can Do To Regain Your Health...

Discover How Laminine™ Can Improve Your Health... Watch The Video Above!

Laminine™ Will Help Anyone. The Benefits, When Taken Regularly May Include...

  • Moderate the Stress Response
  • Maintain Healthy Cortisol Levels
  • Regulate Serotonin Levels
  • Reduce Physical and Mental Stress
  • Help Your Body Recover from Major Illnesses (e.g. Depression, Anxiety, Cancer)
  • Promote More Restful Sleep
  • Build Collagen for Healthier Skin
  • Reduce Signs of Normal Aging
  • Improve Emotional Balance
  • Promote Faster Post Workout Recovery
And Many More Health Benefits Reported By Everyday Users!




  • Enhance Muscle Tone and Strength
  • Improve Stamina and Energy
  • Increase Alertness
  • Aid in Brain Function and Activity (For people suffering from Alzheimer's syndrome, ADD, etc.)
  • Increase Physical and Mental Strength
  • Improve Focus
  • Increase Libido/Sexual Desire
  • Stimulate Natural DHEA Production
  • Improve the Overall Sense of Well-Being

Make 2017... the Year You Improve Your Health!

Join Thousands in 42 Countries (shown at the bottom of this page) Who Are Already Seeing Amazing Health Benefits from Regular Use of Laminine™ & Laminine™ Omega Plus!

"The Happy Pill"

Laminine™ is a Natural, Synergistic SuperFood that contains 22 amino acids, trace minerals, vitamins and Fibroblast Growth Factor (FGF) The perfect combination of life-giving sustenance sourced from land, sea and plant. Its source is from the "Miracle of Life". 

 Clinical Studies have been conducted which showed Laminine's™ positive effects on Physical, Mental, Emotional Strengths and Overall Health. Laminine™ is an all Natural Product
CLICK HERE To Join My Group & Order (Wholesale) & Choose the "Laminine™ Activation Pack"

conflict of interest

The following is a guest post from Andrew Holtz, one of our longtime contributors and a past president of the Association of Health Care Journalists.

“The cornerstone for managing conflicts of interest is transparency…” That phrase introduces the University of Houston’s Policy on Conflict of Interest in Research. It’s a statement with which we strongly agree. And it certainly encompasses researchers holding a patent related to research the university promotes with a news release, wouldn’t you think?

Apparently not.

“I don’t routinely include that, as the news release is aimed at a general audience who is just interested in the more detailed look,” wrote University of Houston Senior Media Relations Specialist Jeannie Kever. It’s a disheartening and confusing response. More on that after some background.

On August 8, 2016, the university announced “Researchers propose new treatment to prevent kidney stones”. The key point of the news release was that lab experiments indicated a fruit extract called hydroxycitrate might be more effective than a chemical cousin, citrate, which is often recommended as a dietary supplement for people prone to kidney stones. Our review of the news release rated it satisfactory on 6 of 10 criteria. But one “unsatisfactory” rating was spectacularly so.

After I took my first look at the release, co-reviewer Yoni Freedhoff, M.D. did something that should be part of every health beat reporter’s routine. He performed a simple online search for the names of the researchers and the word “patent”. And he got a hit: “Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof”. The patent application notes that hydroxycitrate could become a treatment for kidney stones. Freedhoff’s search result was a good catch. “That the authors have a patent on the use of hydroxycitrate in the treatment of kidney stones is an important piece of context given the clear cut conflict of interest,” he said. Keep in mind, the point here is not whether researchers should apply for patents, only whether we should be told about them.

I hadn’t known of the patent (I’m going to use Freedhoff’s search tip from now on) because it wasn’t noted in either the news release or the draft copy of the Nature journal article we had in hand when we did the review. I sent a note to Kever at the University of Houston asking if they had complied with their disclosure policy. She contacted researcher Prof. Jeffrey Rimer, who quickly responded that although it wasn’t mentioned in the manuscript PDF, the final online Nature article did disclose the patent:

“Competing financial interests: J.D.R. and J.R.A. have filed a provisional patent application on the use of organic acids as growth inhibitors of pathological calcification.”

That still left the matter of the news release’s failure to disclose the patent and Kever’s response that, “I don’t routinely include that, as the news release is aimed at a general audience who is just interested in the more detailed look.”

I sharply disagree with the idea that conflict of interest disclosures shouldn’t be included in a release aimed at a “general audience”; that is, anyone not digging down into the footnotes of journal articles, including many reporters and the public. And I’m befuddled by the phrase “who is just interested in the more detailed look.” Maybe there’s a typo in that phrase. I don’t know, because Kever has not responded to several emails and a telephone message asking for clarification.

HealthNewsReview.org publisher Gary Schwitzer notes funding and conflicts of interest are often omitted from news releases. “Only 48 percent of the 224 releases we’ve reviewed as of this moment get a satisfactory score on this criterion: Does the news release identify funding sources & disclose conflicts of interest? So for readers it’s a coin toss whether they’re going to get proper disclosure or not,” he points out.

The omissions in news releases rob the public of important information. In this case, the patent held by the researchers means they have a vested interest in reporting a positive outcome. Studies have shown time and again that, despite researchers’ good faith attempts to remain objective, such financial conflicts of interest may impact the findings of their studies in important ways.

Sad to say, but too few reporters are checking original sources. Indeed, in this case I could not find any mention of the patent in stories available online about the potential kidney stone treatment, even though the disclosure is there for anyone who takes a careful look at the Nature article online. Last week, I tried contacting reporters or editors who worked on stories at the Houston Chronicle, HealthDay/WebMD, the Daily Mail, and HealthNewsline to find out if they knew of the patent and decided not to tell readers, or didn’t know about it, perhaps because they never looked beyond the news release.  

Emails to these news organizations haven’t produced clarity. A staffer at the Daily Mail wrote that the reporter is away on vacation, but he believes they were not aware of the patent. Nothing substantive yet from the other outlets.

So there we are… a tale of conflict of interest disclosure that reveals technical compliance, routine omissions and weak reporting. The result: health news readers who are not given the context they need to fully understand the research and its implications.

The post Conflict of interest/funding disclosure missing from half of news releases we’ve reviewed — a case study on why that’s important appeared first on HealthNewsReview.org.

After Clicking on One of the Links Below, Just CLICK the "Click Here to Agree and Continue" Button in the "Informed Consent and Participation Agreement" Form... to Begin Your Own Personal Q & A Session on How Laminine and Laminine Omega +++ Can Help You Achieve PERFECT Health.

Updated: August 18, 2016 — 3:30 pm

Copyright © 2019 - All Rights Reserved - Site Map - Resources (Add Your Link)

The statements and products referred to throughout this site have not been evaluated by the FDA. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult a physician.

Glenn Freiboth - (815) 524-3752 - CST - [email protected] - Company Site
An Independent Lifepharm® Distributor

Available In The Countries Below: 

Australia, Austria, Belgium, Bosnia-Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ghana, Greece, Hungary, Indonesia, Ireland, Italy, Jamaica, Japan, Kazakhstan, Latvia, Lithuania, Luxembourg, Macedonia, Malaysia, Malta, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Ukraine, United Kingdom, United States - More Countries Coming Soon!